title: Development of a complex parent-metabolite joint population pharmacokinetic model.
abstract: This study aimed to develop a joint population pharmacokinetic model for an antipsychotic agent in development (S33138) and its active metabolite (S35424) produced by reversible metabolism. Because such a model leads to identifiability problems and numerical difficulties, the model building was performed using the FOCE-I and the Stochastic Approximation Expectation Maximization (SAEM) estimation algorithms in NONMEM and MONOLIX, respectively. Four different structural models were compared based on Bayesian information criteria. Models were first written as ordinary differential equations systems and then in closed form (CF) to facilitate further analyses. The impact of polymorphisms on genes coding for the CYP2C19 and CYP2D6 enzymes, respectively involved in the parent drug and the metabolite elimination were investigated using permutation Wald test. The parent drug and metabolite plasma concentrations of 101 patients were analyzed on two occasions after 4 and 8 weeks of treatment at 1, 3, 6, and 24 h following daily oral administration. All configurations led to a two compartment model with back-transformation of the metabolite into the parent drug and a first-pass effect. The elimination clearance of the metabolite through other processes than back-transformation was decreased by 35% [9-53%] in CYP2D6 poor metabolizer. Permutation tests were performed to ensure the robustness of the analysis, using SAEM and CF. In conclusion, we developed a complex joint pharmacokinetic model adequately predicting the impact of CYP2D6 polymorphisms on the parent drug and its metabolite concentrations through the back-transformation mechanism.
authors: INSERM, UMR, Univ Paris Diderot, Sorbonne Paris Cité, UMR, France. julie.bertrand@inserm.fr
authors: Julie
authors: J
authors: Bertrand
authors: Céline M
authors: CM
authors: Laffont
authors: France
authors: F
authors: Mentré
authors: Marylore
authors: M
authors: Chenel
authors: Emmanuelle
authors: E
authors: Comets
references: Pharmacogenetics. 2000 Jul;10(5):373-88
references: 10898107
references: Biometrics. 1990 Sep;46(3):673-87
references: 2242409
references: Clin Chem. 2003 Apr;49(4):542-51
references: 12651805
references: Biopharm Drug Dispos. 1993 Dec;14(9):721-66
references: 8298069
references: J Biopharm Stat. 2008;18(6):1084-102
references: 18991109
references: J Pharmacol Exp Ther. 2008 Mar;324(3):1212-26
references: 18096759
references: Eur J Pharm Sci. 2000;10(4):285-94
references: 10838018
references: Clin Pharmacol Ther. 1992 Apr;51(4):388-97
references: 1345344
references: J Pharmacokinet Pharmacodyn. 2010 Feb;37(1):49-65
references: 20033477
references: Clin Pharmacokinet. 2007;46(3):221-34
references: 17328581
references: J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):317-39
references: 19562469
references: Br J Clin Pharmacol. 2008 Jun;65(6):855-63
references: 18294322
references: Drug Metab Rev. 2009;41(2):89-295
references: 19514967
references: Eur J Clin Pharmacol. 1975 Feb 28;8(2):141-8
references: 1233210
references: J Pharm Pharmacol. 2006 Jul;58(7):871-85
references: 16805946
references: Br J Clin Pharmacol. 2005 Oct;60(4):390-403
references: 16187971
references: Cancer Chemother Pharmacol. 2009 Feb;63(3):517-24
references: 18496691
references: J Clin Psychopharmacol. 2009 Jun;29(3):272-7
references: 19440082
references: Biometrics. 1994 Dec;50(4):1171-7
references: 7786999
references: Drug Metab Dispos. 1997 Jan;25(1):40-6
references: 9010628
references: Comput Methods Programs Biomed. 2008 May;90(2):154-66
references: 18215437
references: Br J Clin Pharmacol. 2008 Nov;66(5):629-39
references: 18771484